SREBF2 and neoplasm: Furthermore, three-dimensional (3D) growth of these cells knocked down for SREBP2 expression was disrupted following statin exposure, indicating that simultaneously targeting HMGCR and SREBP2 is a promising novel anti-tumor therapeutic strategy.